Pooled secondary analysis of two phase 3 RCTs (n=1,874) in COPD with type 2 inflammation (eosinophils ≥300/µL): dupilumab vs placebo cut ED visits/hospital admissions by 38% (rate ratio 0.62) and first-event risk (HR 0.55), with less systemic corticosteroid use.
Secondary analysisn = 1,874
Bhatt et al. Dupilumab in chronic obstructive pulmonary disease: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use